Rockville , Sept. 21, 2023 (GLOBE NEWSWIRE) -- A detailed study by Fact.MR, a market research and competitive intelligence provider, states that the global pegfilgrastim biosimilars market is valued at US$ 1.41 billion in 2023 and is projected to reach US$ 3.66 billion by 2033.
Pegfilgrastim is a synthetic version of granulocyte-colony stimulating factor (G-CSF) used to stimulate the production of white blood cells in patients undergoing chemotherapy. Biosimilars are drugs that are highly similar to reference biologics and offer a more cost-effective alternative. The rapidly rising incidence of cancer and the advancements in oncology treatment are driving demand for pegfilgrastim biosimilars.
Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=1494
Regulatory agencies, such as the United States FDA and the European Medicines Agency (EMA), have established guidelines for biosimilar approvals, which offer a clear and easy path for pegfilgrastim biosimilar manufacturers. The global pegfilgrastim biosimilar market is expected to grow rapidly in the next 10 years as more countries are approving these biosimilars and incorporating them into their healthcare systems.
Rising healthcare costs and the need for cost-effective cancer treatment options are significantly driving the adoption of pegfilgrastim biosimilars. The expiration of patents for reference biologic products is also expected to generate profitable opportunities for pegfilgrastim biosimilar manufacturers.
| Report Attributes | Details |
| Value Projection (2033) | US$ 3.66 Billion |
| Growth Rate (2023-2033) | 10% CAGR |
| No. of Pages | 170 pages |
| No. of Tables | 16 Tables |
| No. of Figures | 49 Figures |
Key Takeaways from Market Study
- Global demand for pegfilgrastim biosimilars is forecasted to increase at a CAGR of 10% from 2023 to 2033.
- North America is seeing the gradual introduction of pegfilgrastim biosimilars due to the presence of supportive regulatory approvals and the need to reduce healthcare costs.
- Innovation and presence of advanced healthcare infrastructure are boosting the sales of pegfilgrastim biosimilars in Europe.
- Asian countries such as India, Japan, and South Korea have been actively producing pegfilgrastim biosimilars to meet the demand for more affordable cancer treatments.
“The concept of biosimilar interchangeability is offering effective treatment options for cancer patients,” says a Fact.MR analyst.
Key Companies Profiled in This Report
- Coherus Biosciences
- Mylan N.V.
- Biocon
- Novartis AG (Sandoz)
- Pfizer Inc.
- Green Cross Corp
- Accord healthcare
- Intas Pharmaceuticals Ltd.
- Zydus Cadila
- Mundipharma
- Fresenius Kabi
Competitive Analysis
Manufacturers are investing heavily in research and development efforts to improve the manufacturing processes and quality of pegfilgrastim biosimilars. Leading pegfilgrastim biosimilar manufacturers are collaborating with healthcare providers to promote the adoption of biosimilars.
- For US$ 3.34 billion, Viatris's biosimilar business was purchased by India-based Biocon Biologics Ltd., a fully integrated biopharmaceutical organization in February 2022. This acquisition is helping Biocon expand its direct-market reach for its existing and future biosimilars.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=1494
Key Segments of Pegfilgrastim Biosimilar Industry Research Report
- By Application:
- Chemotherapy Treatment
- Transplantation
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Mail Order/Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global pegfilgrastim biosimilar market, presenting historical demand data for 2018 to 2022 and forecast statistics for 2023 to 2033.
The study divulges essential insights on the market based on application (chemotherapy treatment, transplantation) and distribution channel (hospital pharmacies, retail pharmacies, mail order/online pharmacies), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and the MEA).
Explore More Trending Studies Published by Fact.MR Research:
Autoinjectors Market: The global autoinjectors market size was valued at US$ 59.04 Billion in 2023, and is predicted to reach US$ 260.45 Billion by 2033.
Breast Cancer Diagnostics Market: The breast cancer diagnostics market is expected to reach nearly US$ 7.9 Billion by 2032.
Polymerase Chain Reaction Market: According to Fact.MR, polymerase chain reaction value will reach US$ 12 Billion by 2031.
About Fact.MR:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we delivers deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empowers businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
